1-amino-2-(1-hydroxy-2-propyl)-8,8-dimethyl-5,6,7,8-tetrahydrophenantrene-3,4-dione

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 1-amino-2-(1-hydroxy-2-propyl)-8,8-dimethyl-5,6,7,8-tetrahydrophenantrene-3,4-dione
• 英文别名: 1-amino-2-(1-hydroxy-2-propyl)-8,8-dimethyl-5,6,7,8-tetrahydrophenanthrene-3,4-dione；1-amino-2-(1-hydroxypropan-2-yl)-8,8-dimethyl-6,7-dihydro-5H-phenanthrene-3,4-dione
• 化学式: C₁₉H₂₃NO₃
• 分子量: 313.397
• InChiKey: QBTDUXWHJAHOGM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  80.4
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  (+/-)-cryptotanshinone 在 氨 作用下， 以 乙醇 、 水 为溶剂， 反应 10.0h， 以50%的产率得到1-amino-2-(1-hydroxy-2-propyl)-8,8-dimethyl-5,6,7,8-tetrahydrophenantrene-3,4-dione
  参考文献：
  名称：

  丹参酮与生物胺代谢产物的体外反应

  摘要：

  隐和丹参酮IIA的与参与肝性脑病的致病途径几个生物胺的代谢物的反应进行了研究和11 1,2,3,4，-tetrahydrophenanthrene衍生物，2 - 10，14和16获得。讨论了可能的反应机理。

  DOI：

  10.1016/s0040-4020(02)01414-x

文献信息

• DIHYDROFURAN CYCLIC TANSHINTONES USED IN TREATING HYPERAMMONEMIA AND HEPATIC ENCEPHALOPATHY
  申请人：Zhongshan University

  公开号：EP1352653A1

  公开（公告）日：2003-10-15

  The present invention relates to use of dihydrofuran cyclic tanshinones represented by the formula (I): wherein R1 is selected from a group consisting of -CH2CH2CH2C(CH3)2-, -CHCHCHC(CH3)-, -CH2CH2CHC(CH3)-, or -CH2CH2CH2C(CH2)-, R2 is H or C1-C3 alkyl etc. or a pharmaceutical composition containing the same for manufacturing medicine in preventing or treatment of hyperammonemia caused by chronic hepatitis and hepatocirrhosis, including hepatic encephalopathy and subclinical hepatic encephalopathy caused by hyperammonemia etc.

  本发明涉及由式(I)代表的二氢呋喃环丹参酮的用途： 其中R1选自由-CH2CH2CH2C(CH3)2-、-CHCHC(CH3)-、-CH2CH2CHC(CH3)-或-CH2CH2CH2C(CH2)-组成的组，R2为H或C1-C3烷基等。或含有相同成分的药物组合物，用于制造预防或治疗慢性肝炎和肝硬化引起的高氨血症的药物，包括高氨血症引起的肝性脑病和亚临床肝性脑病等。
• CRYPTOTANSHINONE FOR PREVENTING AND ALLEVIATING ALZHEIMER'S DISEASE
  申请人：Zhongshan University

  公开号：EP1364648A1

  公开（公告）日：2003-11-26

  The present invention relates to use of Cryptotanshinone represented by formula (1): or a pharmaceutical composition containing the compound for manufacturing drug in preventing and treating early stage AD.

  本发明涉及由式（1）代表的隐丹参酮的用途： 或含有该化合物的药物组合物，用于制造预防和治疗早期 AD 的药物。
• Dihydrofuran cyclic tanshinones used in treating hyperammonemia and hepatic encephalopathy
  申请人：——

  公开号：US20040024056A1

  公开（公告）日：2004-02-05

  The present invention relates to use of dihydrofuran cyclic tanshinones represented by the formula (I): 1 wherein R 1 is selected from a group consisting of —CH 2 CH 2 CH 2 C(CH 3 ) 2 —, —CHCHCHC(CH 3 )—, —CH 2 CH 2 CHC(CH 3 )—, or —CH 2 CH 2 CH 2 C(CH 2 )—, R 2 is H or C 1 -C 3 alkyl etc. or a pharmaceutical composition containing the same manufacturing medicine in preventing or treatment of hypermmonemia caused by chronic hepatitis and hepatocirrhosis, including hepatic encephalopathy and subclinical hepatic encephalopathy caused by hypermmonemia etc.

  本发明涉及由式(I)代表的二氢呋喃环丹参酮的用途： 1 其中 R 1 选自由 -CH 2 CH 2 CH 2 C(CH 3 ) 2 -、-CHCHCHC(CH 3 )-，-CH 2 -、-CHCHC(CH 3 )-、-CH 2 2 CHC(CH 3 )-，或-CH 2 CH 2 或-CH 2 CH 2 2 C(CH 2 )-, R 2 是 H 或 C 1 -C 3 烷基等，或含有相同成分的药物组合物，用于预防或治疗慢性肝炎和肝硬化引起的高血氨症，包括高血氨症引起的肝性脑病和亚临床肝性脑病等。
• Synthesis of new 1,1-dimethyl-1,2,3,4-tetrahydrophenanthrene derivatives
  作者：Xian-Zhang Bu、Zhi-Shu Huang、Min Zhang、Lin Ma、Gui-Wu Xiao、Lian-Quan Gu

  DOI：10.1016/s0040-4039(01)01034-6

  日期：2001.8

  Four new 1,1-dimethyl-1,2,3,4-tetrahydrophenanthrene derivatives. 1-amino-2-(1-hydroxy-2-propyl)-8,8-dimethyl-5,6,7,8-tetrahydrophenanthrene-3,4-dione. 2. 3-amino-2-(1-hydroxy-2-propyl)-8,8-dimethyl-5,6,7,8-tetrahydrophenanthrene-1,4-dione. 3. 1,4,9,0-tetramethyl-4,5,9,10,11,12-hexahydro-1H-6-6oax-1,3-diaza-dicyclopenta[a,c] phenanthrene 4. 2,4,9,9-tetramethyl-4,5,9,10,11,12-hexahydro-1,6-dioxa-3-aza-dicyclopenta[a,c]phenanthrene 5. were synthesized by reactions of cryptotanshinone 1. a bioactive component from Salvia miltiorrhiza bunge, with amino compounds. (C) 2001 Elsevier Science Ltd. All rights reserved.
• Cryptotanshinone for preventing and alleviating alzheimer's disease
  申请人：——

  公开号：US20040039050A1

  公开（公告）日：2004-02-26

  The present invention relates to use of Cryptotanshinone represented by formula (I): 1 or a pharmaceutical composition containing the compound for manufacturing drug in preventing and treating early stage AD.